2014-09, Revenue from Contracts with Customers (ASU 2014-09).
The Company accounted for the acquisition of Cognigen and DILIsym Services, Inc., using the purchase method of accounting where the assets acquired and liabilities assumed are recognized based on their respective estimated fair values.
The provisions of ASU 2016-02 are to be applied using a modified retrospective approach.
The Company holds cash and cash equivalents at banks located in California and North Carolina with balances that often exceed FDIC insured limits.
This plan terminated in February 2017 by its term.
Payments under the Earn-out liability started in FY 2019.
Our contributions to this Plan amounted to $116,839 and $95,585 for the three months ended May 31, 2019 and 2018, respectively and $295,777 and $238,011 for the nine months ended May 31, 2019 and 2018 respectively.
The company measures its consulting revenue based on time expended compared to total estimated hours to complete a project.
Total amortization expense for intellectual property agreements for the three months ended May 31, 2019 and 2018 was $232,292 and $231,042, respectively, and total amortization expense for the nine months ended May 31, 2019 and 2018 was $696,876 and $693,125 respectively.The software will utilize predictions of drug exposure in the kidney from PBPK platforms such as GastroPlus, along with in vitro data related to certain kidney injury mechanisms, to make predictions.
In September 2018, we were pleased to announce that we were awarded another funded RCA by the FDA to integrate drug product quality attributes into the mechanistic TCAT model in GastroPlus.
In addition, we actively seek strategic acquisitions to expand the pharmaceutical software and services business.
Simulation Plus also acquired DILIsym Services, Inc. (DILIsym) as a wholly owned subsidiary.
Consolidated cost of revenues increased by $860,000, or 14.7%, in 9moFY19 to $6.73 million from $5.87 million in 9moFY18.
DDDPlus mechanistically simulates in vitro (laboratory) experiments that measure the rate of dissolution of a drug as well as, if desired, the additives (excipients) in a particular dosage form (e.g., powder, tablet, capsule, or injectable solids) under a variety of experimental conditions.
Version 9.7 was in final testing as of May 31, 2019 and released in June 2019.
GastroPlus mechanistically simulates the absorption, pharmacokinetics, pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals and is currently the most widely used commercial software of its type by pharmaceutical companies, the U.S. Food and Drug Administration (FDA), the U.S. National Institutes of Health (NIH), and other government agencies in the U.S. and other countries.
A pharmacometric analysis is an evolutionary process â€“ one that often results in the creation of hundreds of new program files and code changes to hundreds more due to common typographical and programmatic errors.